Artiva Biotherapeutics, Inc. cotiza a 6.77 USD y tiene una capitalización bursátil de $331M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.63 | $-0.95 | $-0.84 | $-0.88 |
| Estimado | $-0.64 | $-0.84 | $-0.80 | $-0.80 |
| Sorpresa | +1.6% | -13.1% | -5.0% | -10.0% |
| Métrica | ARTV | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -76.3% | -40.4% | -35.9% |
| ROA | -64.0% | -32.0% | -32.0% |
| Current Ratio | 8.61 | 2.84 | +5.77 |
| Debt / Equity | — | 0.28 | — |